DaVita (DVA)
(Delayed Data from NYSE)
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
A Value B Growth C Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Reasons to Retain Inari Medical (NARI) in Your Portfolio Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.
Why DaVita HealthCare (DVA) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Myriad's (MYGN) New Acquisition to Boost Precision Oncology Arm
by Zacks Equity Research
Myriad Genetics (MYGN) is set to acquire certain assets of IPG, including Precise Liquid, which is expected to be launched later this year.
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed (CHE) on the strength of the VITAS Healthcare and Roto-Rooter segments.
Nevro's (NVRO) SCS Therapy Gets Positive Coverage Update
by Zacks Equity Research
Nevro's (NVRO) latest announcement of a positive coverage update from Carelon Healthcare for PDN treatment is likely to serve a wider patient pool.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Quest Diagnostics (DGX) and Fitbit Team Up for New Pilot Study
by Zacks Equity Research
Quest Diagnostics (DGX) partners with Fitbit to study the potential of wearable devices to improve metabolic health.
Penumbra (PEN) Rides on Vascular Arm Strength Amid FX Woes
by Zacks Equity Research
Penumbra's (PEN) Vascular business is demonstrating strong growth, banking on a rapid increase in sales of vascular thrombectomy products in the United States.
Charles River's (CRL) New Launch to Boost Gene Therapy Programs
by Zacks Equity Research
Charles River's (CRL) latest offering is likely to complete a comprehensive range of off-the-shelf plasmid products and simplify gene therapy supply chains with immediate availability.
DexCom's (DXCM) G7 Links With Tandem's Insulin Pump in Europe
by Zacks Equity Research
Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.
Masimo (MASI) Gains on Favorable Ruling in Apple Watch Dispute
by Zacks Equity Research
Masimo (MASI) rides on the continuation of the import ban on certain models of Apple watches using disputed blood oxygen sensors.
Best Growth Stocks to Buy for January 18th
by Zacks Equity Research
DVA, CAH and ZM made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 18, 2024.
Best Value Stocks to Buy for January 18th
by Zacks Equity Research
DVA, CAH and BBVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on January 18, 2024.
New Strong Buy Stocks for January 18th
by Zacks Equity Research
PD, EGO, HMC, DVA and BBVA have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2024.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) on strong uptake of the myAir app with AirSense11.
Abbott's (ABT) Innovations Aid, Macroeconomic Issues Stay
by Zacks Equity Research
Abbott (ABT) is successfully continuing the rollout of Alinity, the company's fully integrated and automated molecular diagnostics analyzer.
ClearPoint Neuro (CLPT) Gets FDA's Nod for SmartFrame OR System
by Zacks Equity Research
ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to serve a wider patient pool than its legacy portfolio.
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) due to its series of new product launches and promising growth strategy.
Here's Why You Should Add McKesson (MCK) to Your Portfolio Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.
Here's Why Investors Should Retain Bruker (BRKR) Stock Now
by Zacks Equity Research
Investors are optimistic about Bruker (BRKR) on solid prospects of BSI Nano group and raised guidance.
Illumina (ILMN) Shares Down 1.2% Post Preliminary Q4 Results
by Zacks Equity Research
Illumina's (ILMN) fourth-quarter 2023 results are likely to reflect the impacts of the adoption of its new generation of distributed liquid biopsy assay.
Should Value Investors Buy DaVita (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.